55103-52-1

Upstream product

• 75-03-6 ethyl iodide 
• 637-88-7 1,4-Cyclohexanedione 
• 4746-97-8 cyclohexanedione monoethylene ketal 
• 22428-87-1 4,4-ethylenedioxycyclohexan-1-ol 
• 74-96-4 ethyl bromide 

Downstream Products

• 950771-78-5 1-[trans-4-(ethyloxy)cyclohexyl]-N-(5-methyl-2-nitrophenyl)-4-piperidinamine 

Relevant academic research and scientific papers

IRAK INHIBITORS AND METHOD FOR MAKING AND USING

Disclosed embodiments concern interleukin receptor associated kinases (IRAK) inhibitors, such as oxazole compounds, and compositions comprising such inhibitors. Also disclosed are methods of making and using the compounds and compositions. The disclosed c

AMIDE COMPOUNDS AND METHOD FOR MAKING AND USING

Disclosed embodiments concern novel interleukin receptor associated kinases (IRAK) inhibitors and compositions comprising such inhibitors. Also disclosed are methods of making and using the compounds and compositions. The disclosed compounds and/or compos

PIPERAZINE DERIVATIVES AS HIV PROTEASE INHIBITORS

The present invention is directed to compounds of Formula I pharmaceutical compositions comprising the same, and their use in the inhibition of HIV protease, the inhibition of HIV replication, the prophylaxis of infection by HIV, the treatment of infection by HIV, and the prophylaxis, treatment, and delay in the onset or progression of AIDS.

1- (1-CYCLOHEXYL-4-PIPERIDINYL) -1, 3-DIHYDRO-2H-BENZIMIDAZOL-2-ONE DERIVATIVES WHICH HAVE ACTIVITY ON THE M1 RECEPTOR AND THEIR USE IN MEDICINE

Compounds of formula (I) or a salt thereof are provided, wherein X1, X2, X3, R6, Q and R are as defined in the description. Uses of the compounds as medicaments and in the manufacture of medicaments for treating

BENZIMIDAZOLES WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE

Compounds of Formula (I) and salts and solvates are provided; wherein R, R5, R6 and Q are defined as in the claims. Uses of the compounds for therapy, for example in the treatment of psychotic disorders and cognitive impairment, are also disclosed.

BENZIMIDAZOLES WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE

Compounds of formula (I), salts and solvates are provided: formula (I), wherein Q, R and R6 are as defined in the claims. Uses of the compounds for therapy, for example in the treatment of psychotic disorders and cognitive impairment, are also disclosed.

New bioorganic reagents: Evolved cyclohexanone monooxygenase - Why is it more selective?

Four mutants of the cyclohexanone monooxygenase (CHMO) evolved as catalysts for Baeyer-Villiger oxidation of 4-hydroxycyclohexanone were investigated as catalysts for a variety of 4-substituted and 4,4-disubstituted cyclohexanones. Several excellent catalytic matches (mutant/substrate) were identified. The most important, however, is the finding that, in a number of cases, a mutant with a single exchange, Phe432Ser, was shown to be as robust and more selective as a catalyst than the wild-type CHMO. All biotransformations were performed on a laboratory scale, allowing full characterization of the products. The absolute configurations of two products were established. A model suggesting a possible role of the 432 serine residue in enantioselectivity control is proposed.

Stereospecific retro-diels-alder fragmentation of stereoisomeric 3- methoxy- and 3,6-dialkoxytricyclo[6.2.2.02,7]dodeca-9-enes upon electron ionization

The stereoisomeric 2,3-cis- and 2,3-trans-3-methoxytricyclo [6.2.2.02,7]dodeca-9-enes endo-1 and exo-1 (endo and exo refer to the methoxy group) exhibit different behavior under electron ionization (EI): the m/z 80 cyclohexa-1,3-diene radical cation formed by retro-Diels-Alder (RDA) fragmentation is the most abundant ion in the 70 eV mass spectrum of endo-1, whereas exo-1 exhibits preferential formation of an m/z 111 ion corresponding to the O-methylcyclohex-2-en-1-one structure (ion a), which may be obtained by an RDA fragmentation accompanied by a hydrogen migration (RDA - H), with the charge retained in the dienophile moiety. A similar effect has been observed in the EI mass spectra of the four stereoisomeric 3-ethoxy-6- methoxytricyclo[6.2.2.02,7]dodeca-9-enes 2; endo-2, with both endo-alkoxy groups, gives rise to the most abundant m/z 80 ion via the regular RDA process, whereas the other three stereoisomers, with at least one exo-alkoxy group, afford the most abundant m/z 155 ions via the RDA - H process, which correspond to the 4-alkoxy-substituted analogues of the m/z 111 ion a obtained from exo-1. Collision-induced dissociation measurements and a deuterium labeling study showed that the m/z 155 ions obtained from the two trans-diethers (trans-2a and trans-2b) have isomeric structures b and c (a mixture of b and c is formed in the case of exo-2), and that the highly stereospecific RDA - H process involves a double hydrogen transfer, one from position 4 to the diene moiety and the other from position 3 to 4. The above stereospecific behavior shows that the thermodynamically favored RDA - H process has a higher activation energy than the regular RDA fragmentation in the case of endo-1 and endo-2. In all other isomers, which have at least one exo-alkoxyl, the activation energy of the RDA - H process is lower than that of RDA. The latter effect is ascribed to anchimeric assistance of the alkoxyl in the initial C - C bond cleavage in the stepwise RAD - H process, which is possible only when at least one alkoxyl has the exo configuration.

Direct evidence for anchimeric assistance in alcohol elimination from gas-phase MH+ ions of 1,4-dialkoxycyclohexanes under chemical ionisation. Experiment and theory

trans-1,4-Dialkoxycyclohexanes afford very abundant [MH - ROH]+ ions upon chemical ionisation (CI), in contrast to the cis-isomers, suggesting anchimeric assistance in the alcohol elimination from the MH+ ions of the trans-diethers. Collision induced dissociation (CID) measurements of the [MH - ROH]+ ions, obtained from various suitably deuterium labelled stereoisomeric 1-ethoxy-4-methoxycyclohexanes, indicated fromation of symmetrical bicyclic ethyl and methyl oxonium ions by an anchimerically assisted alcohol elimination from the trans-diethers. On the other hand these measurements suggest that the cis-isomers afford isomeric monocyclic O-protonated 4-alkoxycyclohexene cations, in which the hydrogens at positions 2 and 3 (as well as those at positions 5 and 6, and 1 and 4) are not equivalent. The two results, namely the symmetrical bicyclic structure and the high abundance of the [MH - ROH]+ ions in the CI mass spectra of the trans-diethers, in contrast to the non-symmetrical monocyclic structure and low abundance of these ions in the cis-isomers, are suggested to be direct evidence for anchimeric assistance in a gas-phase ion dissociation process. Ab initio calculations at the MP3/6-31G*//6-31G* level support the anchimerically assisted elimination mechanism observed in trans-1-ethoxy-4-methoxycyclohexane, but also show that the energy difference between the anchimerically assisted and non-assisted elimination mechanisms is small (ca. 2-3 kcal mol-1)(1 cal = 4.184 J).